CD133+ HCC cells have previously been shown to have increased tumorigenicity and to be resistant to chemotherapy drugs via the activation Akt signaling and pro-survival Bcl-2 pathways [44]. The gene discussed is AKT1; the disease is hepatocellular carcinoma.